Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
| ▸ | ADH7 | P40394 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5514448 | 0.75 | ALDH1A1 (0.36) | — | |
| SCHEMBL5254185 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2CA12CA2CA9ADH1B | |
| SCHEMBL15218404 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2CA12CA2CA9ADH1B | |
| SCHEMBL8765643 | 0.72 | TGM2 (0.31) | — | |
| SCHEMBL10127349 | 0.72 | — | — | |
| SCHEMBL25511677 | 0.72 | TGM2 (0.31) | — | |
| SCHEMBL5514451 | 0.71 | — | — | |
| SCHEMBL1726872 | 0.71 | SMN1; SMN2 (0.48) | SMN1; SMN2CA12CA2CA9 | |
| SCHEMBL291950 | 0.71 | SMN1; SMN2 (0.48) | SMN1; SMN2CA12CA2CA9 | |
| SCHEMBL291951 | 0.71 | SMN1; SMN2 (0.48) | SMN1; SMN2CA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213122-A1 | SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS | NUVATION BIO INC (US) | 2022-07-07 | — | — | US | disclosed |
| US-11192900-B2 | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors | NUVATION BIO INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200140459-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213122-A1 | SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS | BET1, BRD4, BRD3 | SMN1; SMN2 2183/4885CA12 4818/4885CA2 4663/4885 |
| US-20200140459-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | SMN1; SMN2 2600/4885CA12 4819/4885CA2 4714/4885 |
| US-11192900-B2 | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors | BET1, BRD4, PHKB | SMN1; SMN2 1773/4885CA12 4881/4885CA2 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.